These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33530812)

  • 1. Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics.
    Mahmoudian M; Valizadeh H; Löbenberg R; Zakeri-Milani P
    J Microencapsul; 2021 May; 38(3):192-202. PubMed ID: 33530812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib.
    Korani M; Korani S; Zendehdel E; Jaafari MR; Sathyapalan T; Sahebkar A
    Anticancer Agents Med Chem; 2020; 20(6):643-650. PubMed ID: 31985384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
    Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
    Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of the intestinal absorption of bortezomib by self-nanoemulsifying drug delivery system.
    Mahmoudian M; Valizadeh H; Löbenberg R; Zakeri-Milani P
    Pharm Dev Technol; 2020 Mar; 25(3):351-358. PubMed ID: 31810410
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
    Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
    J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
    Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
    Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.
    de la Puente P; Luderer MJ; Federico C; Jin A; Gilson RC; Egbulefu C; Alhallak K; Shah S; Muz B; Sun J; King J; Kohnen D; Salama NN; Achilefu S; Vij R; Azab AK
    J Control Release; 2018 Jan; 270():158-176. PubMed ID: 29196043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycine-Poly-L-Lactic Acid Copolymeric Nanoparticles for the Efficient Delivery of Bortezomib.
    Rajoria S; Rani S; Chaudhari D; Jain S; Gupta U
    Pharm Res; 2019 Sep; 36(11):160. PubMed ID: 31520196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib-loaded solid lipid nanoparticles: preparation, characterization, and intestinal permeability investigation.
    Mahmoudian M; Valizadeh H; Zakeri-Milani P
    Drug Dev Ind Pharm; 2018 Oct; 44(10):1598-1605. PubMed ID: 29874944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biotinylated HPMA centered polymeric nanoparticles for Bortezomib delivery.
    Rani S; Sahoo RK; Nakhate KT; Ajazuddin ; Gupta U
    Int J Pharm; 2020 Apr; 579():119173. PubMed ID: 32097684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
    Arkwright R; Pham TM; Zonder JA; Dou QP
    Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy.
    Shen S; Du XJ; Liu J; Sun R; Zhu YH; Wang J
    J Control Release; 2015 Jun; 208():14-24. PubMed ID: 25575864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations.
    Liu J; Zhao R; Jiang X; Li Z; Zhang B
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PEGylated Dendrimer Mediated Delivery of Bortezomib: Drug Conjugation versus Encapsulation.
    Sahoo RK; Gothwal A; Rani S; Nakhate KT; Ajazuddin ; Gupta U
    Int J Pharm; 2020 Jun; 584():119389. PubMed ID: 32380027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic anticancer activity of combined histone deacetylase and proteasomal inhibitor-loaded zein nanoparticles in metastatic prostate cancers.
    Thapa RK; Nguyen HT; Jeong JH; Shin BS; Ku SK; Choi HG; Yong CS; Kim JO
    Nanomedicine; 2017 Apr; 13(3):885-896. PubMed ID: 27993720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma.
    Federico C; Alhallak K; Sun J; Duncan K; Azab F; Sudlow GP; de la Puente P; Muz B; Kapoor V; Zhang L; Yuan F; Markovic M; Kotsybar J; Wasden K; Guenthner N; Gurley S; King J; Kohnen D; Salama NN; Thotala D; Hallahan DE; Vij R; DiPersio JF; Achilefu S; Azab AK
    Nat Commun; 2020 Nov; 11(1):6037. PubMed ID: 33247158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing the efficiency of bortezomib conjugated to pegylated gold nanoparticles: an in vitro study on human pancreatic cancer cells and adenocarcinoma human lung alveolar basal epithelial cells.
    Coelho SC; Almeida GM; Santos-Silva F; Pereira MC; Coelho MA
    Expert Opin Drug Deliv; 2016 Aug; 13(8):1075-81. PubMed ID: 27087021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development.
    Shen J; Wang R; Wang Q; Zhang M; Liu C; Tao Z; Su G
    Aging (Albany NY); 2020 Dec; 13(1):411-423. PubMed ID: 33290262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib-Encapsulated Dual Responsive Copolymeric Nanoparticles for Gallbladder Cancer Targeted Therapy.
    Chen M; Juengpanich S; Li S; Topatana W; Lu Z; Zheng Q; Cao J; Hu J; Chan E; Hou L; Chen J; Chen F; Liu Y; Jiansirisomboon S; Gu Z; Tongpeng S; Cai X
    Adv Sci (Weinh); 2022 Mar; 9(7):e2103895. PubMed ID: 35068071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib.
    Tan CRC; Abdul-Majeed S; Cael B; Barta SK
    Clin Pharmacokinet; 2019 Feb; 58(2):157-168. PubMed ID: 29802543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.